52-Week Low Stocks
BSX occurs in the near 52-week low stock list, indicating it is a potential value opportunity.
BOSTON SCIENTIFIC CORP (BSX) Stock Price & Overview
NYSE:BSX • US1011371077
Current stock price
61 USD
-1.07 (-1.72%)
Last:
The current stock price of BSX is 61 USD. Today BSX is down by -1.72%. In the past month the price decreased by -11.54%. In the past year, price decreased by -39.09%.
BSX Key Statistics
52-Week Range59.385 - 109.5
Current BSX stock price positioned within its 52-week range.
1-Month Range59.385 - 70.13
Current BSX stock price positioned within its 1-month range.
- Market Cap
- 90.657B
- P/E
- 19.68
- Fwd P/E
- 15.45
- EPS (TTM)
- 3.10
- Dividend Yield
- N/A
BSX Stock Performance
Today
-1.72%
1 Week
-3.36%
1 Month
-11.54%
3 Months
-32.90%
Longer-term
6 Months -38.61%
1 Year -39.09%
2 Years -13.64%
3 Years +19.09%
5 Years +42.36%
10 Years +183.17%
BSX Stock Chart
BSX Stock Screens
BSX currently appears in the following ChartMill screener lists.
BSX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BSX. When comparing the yearly performance of all stocks, BSX is a bad performer in the overall market: 91.82% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
BSX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to BSX. BSX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BSX Earnings
On April 22, 2026 BSX reported an EPS of 0.8 and a revenue of 5.20B. The company beat EPS expectations (0.64% surprise) and missed revenue expectations (-0.36% surprise).
Next Earnings DateJul 21, 2026
Last Earnings DateApr 22, 2026
PeriodQ1 / 2026
EPS Reported$0.80
Revenue Reported5.203B
EPS Surprise 0.64%
Revenue Surprise -0.36%
BSX Forecast & Estimates
41 analysts have analysed BSX and the average price target is 101.73 USD. This implies a price increase of 66.78% is expected in the next year compared to the current price of 61.
For the next year, analysts expect an EPS growth of 14.33% and a revenue growth 10.74% for BSX
Analysts
Analysts84.88
Price Target101.73 (66.77%)
EPS Next Y14.33%
Revenue Next Year10.74%
BSX Groups
Sector & Classification
Sector
Health Care Sub-Industry
Health Care Equipment BSX Financial Highlights
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 3.1. The EPS increased by 14.81% compared to the year before.
Income Statements
Revenue(TTM)20.61B
Net Income(TTM)2.90B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.44% | ||
| ROA | 6.64% | ||
| ROE | 11.96% | ||
| Debt/Equity | 0.46 |
Chartmill High Growth Momentum
EPS Q2Q%6.67%
Sales Q2Q%11.58%
EPS 1Y (TTM)14.81%
Revenue 1Y (TTM)17.44%
BSX Ownership
Ownership
Inst Owners94.54%
Shares1.49B
Float1.48B
Ins Owners0.16%
Short Float %1.59%
Short Ratio1.37
BSX Latest News, Press Relases and Analysis
5 days ago - By: Chartmill
9 days ago - By: Chartmill
20 days ago - By: Chartmill
BSX Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 40.74 | 171.27B | ||
| ABT | ABBOTT LABORATORIES | 14.79 | 158.354B | ||
| SYK | STRYKER CORP | 21.64 | 125.43B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.03 | 48.516B | ||
| IDXX | IDEXX LABORATORIES INC | 38.68 | 44.946B | ||
| BDX | BECTON DICKINSON AND CO | 11.12 | 43.32B | ||
| RMD | RESMED INC | 17.99 | 32.028B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.62 | 31.406B | ||
| DXCM | DEXCOM INC | 24.23 | 23.696B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.95 | 17.665B | ||
| PODD | INSULET CORP | 29.17 | 13.129B | ||
| PEN | PENUMBRA INC | 64.52 | 12.971B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BSX
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
IPO: 1992-05-19
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 59000
Phone: 13026365400
BOSTON SCIENTIFIC CORP / BSX FAQ
What does BOSTON SCIENTIFIC CORP do?
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
What is the current price of BSX stock?
The current stock price of BSX is 61 USD. The price decreased by -1.72% in the last trading session.
What is the dividend status of BOSTON SCIENTIFIC CORP?
BSX does not pay a dividend.
How is the ChartMill rating for BOSTON SCIENTIFIC CORP?
BSX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Would investing in BOSTON SCIENTIFIC CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BSX.
What is BOSTON SCIENTIFIC CORP worth?
BOSTON SCIENTIFIC CORP (BSX) has a market capitalization of 90.66B USD. This makes BSX a Large Cap stock.